Litcius/Paper detail

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó, Ross Bray, Bram Brouwers, Ángel Rodríguez

2022The Lancet Diabetes & Endocrinology482 citationsDOI

Topics & Concepts

MedicineMetforminAdipose tissueType 2 diabetesInternal medicineClinical endpointDiabetes mellitusInsulinEndocrinologyGastroenterologyClinical trialLiver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Disease and Adiposity
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial | Litcius